| DC65838 |
CFT8919
Featured
|
|
|
| DC65839 |
MC1 Precursor
Featured
|
Precursor of MC1, is a vital component in the synthesis of MC1, a selective and potent COX-2 inhibitor. Radiolabeled MC1, [¹¹C]MC1, serves as a promising PET radioligand for imaging COX-2 expression in vivo. Its high selectivity, combined with its ability to non-invasively visualize COX-2 in disease states, makes it a valuable tool for research and clinical applications, particularly in neuroinflammation, cancer, and drug development. |
|
| DC65840 |
KYM-001
Featured
|
|
|
| DC65841 |
MC1
Featured
|
MC1 is a selective and potent COX-2 inhibitor, and its radiolabeled form, [¹¹C]MC1, is a promising PET radiotracer for detecting COX-2 expression in vivo. Its ability to visualize COX-2 in neuroinflammation and other disease states makes it a valuable tool for research and therapeutic development, particularly in understanding and targeting COX-2-mediated processes in the brain.
|
|
| DC65842 |
0G416
Featured
|
|
|
| DC65843 |
HC-X029
Featured
|
|
|
| DC65844 |
ICP-490
Featured
|
|
|
| DC65845 |
GT-919
Featured
|
|
|
| DC65846 |
MGD molecule
Featured
|
|
|
| DC60547 |
ZNL-0056
Featured
|
ZNL-0056 is an ATP-competitive inhibitor that targets both the Cys797 and Cys775 in the ATP binding site of EGFR, which is the first compound capable of targeting a nonconserved and partially buried Cys775. |
|
| DC60551 |
Compound 181
Featured
|
Compound 181 is a selective and highly potent stabilizer of the 14-3-3σ/ERα complex. Compound 181 shows potency comparable to the natural product Fusicoccin-A. |
|
| DC60553 |
Mosnodenvir ( JNJ-1802)
Featured
|
Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates. |
|
| DC65848 |
1,2-didecanoyl-sn-glycero-3-phosphate (sodium salt)
Featured
|
1,2-didecanoyl-sn-glycero-3-phosphate is one kind of phosphatidic acid, which is a minor constituent of biological membranes is a simplest glycerophospholipid. It has glycerol backbone with phosphate present at C-3 position. The C-1 and C-2 positions are esterified with fatty acids.It is used as a component in the lipid bilayer to study how lipid geometry acts in coat protein I (COPI) vesicle fission, and maybe used to activate protein kinase C (PKC). |
|
| DC65851 |
CL15F6
Featured
|
CL15F6 is an ionizable cationic lipid (pKa = 6.75).1 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA and polymer-lipid hybrid nanoparticles for the delivery of plasmid DNA in vitro.1,2 |
|
| DC60557 |
Compound 11 (EBP inhibitor)
Featured
|
Compound 11 (EBP inhibitor) is a selective orally bioavailable, brain-penetrant emopamil binding protein (EBP) inhibitor with EC50 of 44 nM. Compound 11 enhances the formation of oligodendrocytes in human cortical organoids. |
.png)
|
| DC60558 |
Lung endothelium-targeted Lipid-1
Featured
|
Lung endothelium-targeted Lipid-1 is used in pulmonary endothelium targeted mRNA delivery. Lung endothelium-targeted Lipid-1 formulated nanoparticle, Lung-LNP (LuLNP) is capable of delivering therapeutic mRNA cargo for vascular repair in influenza infection. |
|
| DC65859 |
CRT0066101
Featured
|
CRT0066101 is a PRKDs inhibitor. CRT0066101 suppressed the proliferation and migration of four bladder cancer cell lines in vitro. CRT0066101 blocked tumor growth in a mouse flank xenograft model of bladder cancer. CRT0066101 treatment or PKD2 silencing arrested bladder cancer cells at the G2/M phase, the arrest being accompanied by decreases in the levels of cyclin B1, CDK1 and phospho-CDK1 (Thr161) and increases in the levels of p27Kip1 and phospho-CDK1 (Thr14/Tyr15). CRT0066101 suppresses bladder cancer growth by inhibiting PKD2 through induction of G2/M cell cycle arrest, leading to the blockade of cell cycle progression. |
.jpg)
|
| DC65860 |
HA155
Featured
|
HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM. |
|
| DC65861 |
PF-CBP1
Featured
|
PF-CBP1, also known as PF-06670910, is potent and highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) that down regulates targets of CBP in macrophages primary neurons. |
|
| DC65862 |
GSK-3 Inhibitor XIII
Featured
|
GSK-3 Inhibitor XIII is a potent and ATP-competitive GSK-3 inhibitor with a Ki of 24 nM. |
|
| DC65863 |
Ac-trineapac
Featured
|
|
|
| DC65864 |
1-(5-bromo-2-chlorobenzyl)-4-(4-methoxybenzyl)piperazine
Featured
|
|
|
| DC65865 |
tert-butyl 2-(4-(5-(methylcarbamoyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetate
Featured
|
|
|
| DC65866 |
Methyl 4-((2-(piperidin-1-ylmethyl)-1H-benzo[d]imidazol- 5-yl)carbamoyl)benzoate
Featured
|
|
|
| DC65867 |
(S)-N-(5-(6-fluoropyridin-3-yl)-2,3-dihydro-1H-inden-2-yl)propane-2-sulfonamide
Featured
|
|
|
| DC65868 |
NIH-1
Featured
|
|
|
| DC65869 |
N1,N2-bis(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine
Featured
|
|
|
| DC65870 |
NVOC cage-TMP-Halo
Featured
|
NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research. |
|
| DC65871 |
Phylloflavan
Featured
|
Phylloflavan is an antileishmanial agent with an intracellular EC50 of 3.2 nM in RAW 264.7 cells. Phylloflavan also inhibits the cytopathic effect of encephalomyocarditis virus on L929 fibroblast cells (38 U/mL). |
|
| DC65872 |
Comp-43
Featured
|
|
|
